PCLOF (PharmaCielo) Interest Coverage: 1.41 (As of Dec. 2025) — 100% Below Median


What is PharmaCielo Interest Coverage?

PharmaCielo PCLOF -4.35% Interest Coverage is 1.41 as of Dec. 2025, which is 100% below its 10-year median of 10,000.00. The stock has 5 warning signs investors should review. Among 685 Drug Manufacturers companies, PharmaCielo ranks worse than 145985.26% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. PharmaCielo's Operating Income for the three months ended in Dec. 2025 was $0.49 Mil. PharmaCielo's Interest Expense for the three months ended in Dec. 2025 was $-0.35 Mil. PharmaCielo's interest coverage for the quarter that ended in Dec. 2025 was 1.41. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for PharmaCielo's Interest Coverage or its related term are showing as below:


PCLOF's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.78
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


PharmaCielo  (OTCPK:PCLOF) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


PharmaCielo Interest Coverage Related Terms


PharmaCielo Interest Coverage Historical Data

* Premium members only.

The historical data trend for PharmaCielo's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

PharmaCielo Interest Coverage Chart

PharmaCielo Annual Data
Trend Aug17 Aug18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

PharmaCielo Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.41

PCLOF vs ZTS: Interest Coverage Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PharmaCielo's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaCielo Interest Coverage vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PharmaCielo's Interest Coverage distribution charts can be found below:

* The bar in red indicates where PharmaCielo's Interest Coverage falls into.



PharmaCielo Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

PharmaCielo's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, PharmaCielo's Interest Expense was $-2.01 Mil. Its Operating Income was $-7.49 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.90 Mil.

PharmaCielo did not have earnings to cover the interest expense.

PharmaCielo's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Here, for the three months ended in Dec. 2025, PharmaCielo's Interest Expense was $-0.35 Mil. Its Operating Income was $0.49 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Interest Coverage=-1* Operating Income (Q: Dec. 2025 )/Interest Expense (Q: Dec. 2025 )
=-1*0.491/-0.349
=1.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of 1.41 mean?
PharmaCielo (PCLOF) has a Interest Coverage of 1.41 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on PharmaCielo and its competitors. This is 100% below median its historical median of 10,000.00. According to the industry distribution chart, PharmaCielo ranks #999999 out of 685 companies in the Drug Manufacturers industry.
Is PharmaCielo's Interest Coverage too high?
PharmaCielo's current Interest Coverage of 1.41 is 100% below median its 10-year median of 10,000.00. The Drug Manufacturers industry median Interest Coverage is 12.78. PharmaCielo's value of 1.41 is 89% below this industry median. Based on the distribution chart, PharmaCielo ranks #999999 out of 685 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does PharmaCielo's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, PharmaCielo ranks #999999 out of 685 companies for Interest Coverage. This places PharmaCielo in the lower half of its industry. The industry median Interest Coverage is 12.78. PharmaCielo's value of 1.41 is 89% below this benchmark. While the company's 10-year median is 10,000.00 vs. the industry median of 12.78, PharmaCielo has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCielo's current Interest Coverage of 1.41 is 89% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on PharmaCielo and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCielo's current Interest Coverage is 1.41, which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.10, compared to a current price of $0.05 — trading 48.5% below its estimated fair value. The current Interest Coverage is 1.41, which is 100% below median its 10-year median of 10,000.00 and 89% below the Drug Manufacturers industry median of 12.78. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current Interest Coverage is 1.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCielo Business Description

Other Exchanges PCLO:Canada
Address 82 Richmond Street East, Suite 805, Toronto, ON, CAN, M5C 1P1
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.